Abbvie withdraws from cancer candidate collaboration with Genmab

The US-based biotech company will no longer help partner Genmab develop a specific cancer candidate, leaving the Danish firm with sole responsibility and low single-digit royalties due to Abbvie.

Photo: PR / Genmab

Genmab, a Danish biotech firm, has several ongoing oncology collaboration projects with US-based biotech firm Abbvie.

The partnership’s headline candidate is the substance epcoritamab, a potential treatment of relapsed or refractory large B-cell lymphoma (LBCL), a type of non-Hodgkin lymphoma, which Genmab is planning to submit for market authorization in the US within the next few months.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs